MARKET

KLRS

KLRS

Kalaris Therapeutics Inc
NASDAQ
4.320
+0.020
+0.47%
After Hours: 4.320 0 0.00% 16:55 06/26 EDT
OPEN
4.430
PREV CLOSE
4.300
HIGH
4.485
LOW
4.250
VOLUME
164.53K
TURNOVER
--
52 WEEK HIGH
11.88
52 WEEK LOW
2.140
MARKET CAP
102.78M
P/E (TTM)
-1.9509
1D
5D
1M
3M
1Y
5Y
1D
Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients
PUBT · 5d ago
KALARIS ANNOUNCES UPCOMING PRESENTATION OF TH103 PHASE 1A CLINICAL DATA AT AMERICAN SOCIETY OF RETINA SPECIALISTS; PH 1B/2 CLINICAL TRIAL ACTIVELY ENROLLING
Reuters · 5d ago
Weekly Report: what happened at KLRS last week (0615-0619)?
Weekly Report · 6d ago
Weekly Report: what happened at KLRS last week (0608-0612)?
Weekly Report · 06/15 10:34
Kalaris Therapeutics initiated with a Buy at TD Cowen
TipRanks · 06/15 10:10
Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market
TipRanks · 06/15 09:59
KALARIS THERAPEUTICS INC <KLRS.O>: TD COWEN INITIATES COVERAGE WITH BUY RATING
Reuters · 06/15 09:41
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
Reuters · 06/15 07:49
More
About KLRS
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).

Webull offers Kalaris Therapeutics Inc stock information, including NASDAQ: KLRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRS stock methods without spending real money on the virtual paper trading platform.